Spatiotemporal trends and ecological determinants of cardiovascular mortality among 2844 counties in mainland China, 2006–2020: a Bayesian modeling study of national mortality registries

Wei Wang(National Center for Chronic and Noncommunicable Disease Control and Prevention), Maigeng Zhou(National Center for Chronic and Noncommunicable Disease Control and Prevention), Jiangmei Liu(Chinese Center For Disease Control and Prevention), Yong Huo(Sun Yat-sen University), Pengpeng Ye(University of Washington), Jinlei Qi(National Center for Chronic and Noncommunicable Disease Control and Prevention), Chengdong Xu(Institute of Geographic Sciences and Natural Resources Research), Limin Wang(Texas Christian University), Junming Li(Minzu University of China), Jinling You(National Center for Chronic and Noncommunicable Disease Control and Prevention), Peng Yin(National Center for Chronic and Noncommunicable Disease Control and Prevention), Lijun Wang(National Center for Chronic and Noncommunicable Disease Control and Prevention), Ziwei Song, Lin Lin(China Academy of Chinese Medical Sciences), Yunning Liu(National Center for Chronic and Noncommunicable Disease Control and Prevention)
BMC Medicine
November 30, 2022
10.1186/s12916-022-02613-9
Cited by 13

Related Papers

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet|2016|7.8k
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
|The Lancet|2015|6.5k
Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet|2019|3.8k
Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013
|The Lancet|2015|1.5k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k